Publications
Publications 1851 - 1875 de 33557
| Titre | DOI |
|---|---|
|
Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST. P. Schoffski; O. Mir; B. Kasper; Z. Papai; J.Y. Blay; A. Italiano; C. Benson; K. Kopeckova; N. Ali; P. Dileo; A. Le Cesne; F. Menge; S. Cousin; C. Charon-Barra; A. Wozniak; S. Marreaud; S. Litiere; A. Nzokirantevye; H. Gelderblom 2019 |
|
|
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study M. Toulmonde; J.Y. Blay; O. Bouche; O. Mir; N. Penel; N. Isambert; F. Duffaud; E. Bompas; T. Esnaud; R. Boidot; D. Geneste; F. Ghiringhelli; C. Lucchesi; C.A. Bellera; F. Le Loarer; A. Italiano 2019 |
10.1158/1078-0432.CCR-18-3127 |
|
Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE N. Gassian; A. Frontczak; G. Mouillet; D. Vernerey; O. Manseur; M. Goujon; A. Meurisse; D. Berthod; E. Robert; F. Calcagno; A. Thiery-Vuillemin 2020 |
|
|
Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE N. Gassian; A. Frontczak; G. Mouillet; D. Vernerey; O. Manseur; M. Goujon; A. Meurisse; D. Berthod; E. Robert; F. Calcagno; A. Thiery-Vuillemin 2020 |
|
|
Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN) A. Patsouris; A.L. Septans; M.J. Paillard; X. Pivot; P. Soibinet; N. Jovenin; M. Robert; C. Gourmelon; C. Korembaum; T. Petit; J. Martin-babau; A. Brunot; C. Lefeuvre-Plesse; M. Adele; H. Bourgeois; M. Som; L. Uwer; M. Campone; L. Campion; O. Tredan 2015 |
10.1016/S0959-8049(16)30815-2 |
|
Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202. R. Sanfilippo; R.L. Hayward; J. Musoro; C. Benson; M.Gordon Leahy; A. Brunello; J.Y. Blay; N. Steeghs; I.M.E. Desar; N. Ali; A. Hervieu; K. Thway; S. Marreaud; S. Litiere; H. Gelderblom 2020 |
|
|
Activity of Crizotinib in MET Amplified NSCLC: Preliminary Results of the AcSe Trial D. Moro-Sibilot; M.C. Le Deley; G. Zalcman; S. Bota; R. Sabatier; P.Jean Souquet; L. Favier; M. Poudenx; P. Bombaron; C. Audigier-Valette; P. Bernard; P. Foucher; N. Girard; J.P. Merlio; L. Arnould; G. Ferretti; T. Mortier; E. Lonchamp; G. Vassal; C.MahierAit Oukhatar 2015 |
|
|
Activity of Crizotinib in MET Amplified NSCLC: Preliminary Results of the AcSe Trial D. Moro-Sibilot; M.C. Le Deley; G. Zalcman; S. Bota; R. Sabatier; P.Jean Souquet; L. Favier; M. Poudenx; P. Bombaron; C. Audigier-Valette; P. Bernard; P. Foucher; N. Girard; J.P. Merlio; L. Arnould; G. Ferretti; T. Mortier; E. Lonchamp; G. Vassal; C.MahierAit Oukhatar 2015 |
|
|
Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSe Program. G. Vassal; M.C. Ledeley; C. Tournigand; T. Aparicio; I. Ray-Coquard; L. Taillandier; B. Escudier; B. You; A. Goncalves; C.Lombard Bohas; J.Francois Seitz; T. Andre; J.P. Merlio; L. Arnould; G. Ferretti; Y. Menu; T. Mortier; E. Lonchamp; C.MahierAit Oukhatar; D. Moro-Sibilot 2015 |
10.1200/jco.2015.33.15_suppl.2595 |
|
Activity of Different Antistaphylococcal Therapies, A one or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant S. Albac; D. Labrousse; D. Hayez; N. Anzala; D. Bonnot; P. Chavaneta; E. Aslangul; D. Croisier 2020 |
10.1128/AAC.01865-19 |
|
Activity of docetaxel (D) and new generation hormonotherapies (NGH) in patients with metastatic castrate-resistant prostate cancer (mCRPC) following front line cabazitaxel (C). D. Pouessel; S.Aarab Terrisse; G. Mouillet; K. Breitkopf; C. Theodore; F.Joly Lobbedez; G. Roubaud; A. Flechon; J.M. Tourani; C. Massard; A. Thiery-Vuillemin; S. Oudard; E. Sevin; S. Chevret; S. Culine 2015 |
10.1200/jco.2015.33.15_suppl.e16094 |
|
Activity of neural reward circuits in response to food odors: an fMRI study of liking and wanting T. Jiang; R. Soussignan; B. Schaal; J.P. Royet 2015 |
|
|
Activity of neural reward circuits in response to food odors: an fMRI study of liking and wanting T. Jiang; R. Soussignan; B. Schaal; J.P. Royet 2015 |
|
|
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. R.S. Herbst; I. Chau; D.Peter Petrylak; H.T. Arkenau; J.C. Bendell; R. Santana-Davila; E. Calvo; N. Penel; J. Martin-Liberal; A.O. Soriano; P.Alexandre Cassier; M. Krebs; N. Isambert; R. Widau; G. Mi; J. Jin; D.Raymond Ferry; C.S. Fuchs; L.G. Paz-Ares 2018 |
10.1200/JCO.2018.36.15_suppl.3059 |
|
Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS) - results of a double-blind, randomized placebo (PL) controlled phase-II-trial T. Brodowicz; O. Mir; J. Wallet; A. Italiano; A. Le Cesne; J.I. Blay; T. Ryckewaert; F. Bertucci; S. Piperno-Neumann; F. Ploner; M. Toulmonde; J. Domont; E. Saada; E. Lindner; B. Lieg-Atzwanger; N. Penel 2016 |
|
|
Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a doubleblind, randomized placebo (PL) controlled phase II trial O. Mir; T. Brodowicz; J. Wallet; A. Italiano; A. Le Cesne; J.Y. Blay; T. Ryckewaert; F. Bertucci; S. Piperno-Neumann; F. Ploner; M. Toulmonde; J. Domont; E. Saada; C. Delcambre; N. Isambert; S.Clisant Delaine; S. Taieb; E. Lindner; B. Lieg-Atzwanger; N. Penel 2015 |
|
|
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients A.E. Frankel; J.H. Woo; C. Ahn; N. Pemmaraju; B.C. Medeiros; H.E. Carraway; O. Frankfurt; S.J. Forman; X.A. Yang; M. Konopleva; F. Garnache-Ottou; F. Angelot-Delettre; C. Brooks; M. Szarek; E. Rowinsky 2014 |
10.1182/blood-2014-04-566737 |
|
Activity of tepotinib in hepatocellular carcinoma (HCC) with high-level MET amplification (METamp): Preclinical and clinical evidence. S.J. Faivre; J.F. Blanc; H. Pan; V. Grando; H.Yeong Lim; A.Cubillo Gracian; N. Isambert; A. Johne; K. Schumacher; C. Stroh; M. Friese-Hamim; A. O'Brate; D. Zhou; S. Qin 2021 |
10.1200/JCO.2021.39.3_suppl.329 |
|
Actors with stretchable access patterns K. Du; S. Domas; M. Lenczner 2019 |
10.1016/j.vlsi.2019.01.001 |
|
Actual and Imagined Movements Reveal a Dual Role of the Insular Cortex for Motor Control C. Rousseau; M. Barbiero; T. Pozzo; C. Papaxanthis; O. White 2021 |
10.1093/cercor/bhaa376 |
|
Actuated MOEMS Micro-Mirror based on PMN-PT Piezoelectric Material D.Adrian Ciubotariu; C. Cleevy; P. Lutz; I.Alexandru Ivan 2014 |
10.1109/ISOT.2014.51 |
|
Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastrointestinal Motility and Improves Postprandial Glycemia in Mice S. Troy-Fioramonti; L. Demizieux; J. Gresti; T. Muller; B. Verges; P. Degrace 2015 |
10.2337/db14-0721 |
|
Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs P.B. Pages; V. Derangere; O. Bouchot; G. Magnin; C. Charon-Barra; F. Lokiec; F. Ghiringhelli; A. Bernard 2015 |
10.1093/ejcts/ezu441 |
|
Acute angle closure attack secondary to a cavernous sinus dural fistula P. Goin; H. Charpentier; M. Delattre; B. Delbosc; A.S. Gauthier 2020 |
10.1016/j.jfo.2020.01.011 |
|
Acute appendicitis: Factors associated with inconclusive ultrasound study and the need for additional computed tomography M. Pelin; B. Paquette; L. Revel; M. Landecy; S. Bouveresse; E. Delabrousse 2018 |
10.1016/j.diii.2018.07.004 |